Viridian Therapeutics Aktie Logo
US92790C1045
A2QMUH
VRDN

Viridian Therapeutics Aktie

Prognoza

Średnia cena docelowa analityków wynosi 36,45 € (+33,52%). Mediana wynosi 35,54 € (+30,18%).

Kupuj
  15
Trzymaj
  2
Sprzedaj
  0

Dyskusje w społeczności

Nie ma jeszcze dyskusji o tym aktywie.

Rozpocznij dyskusję

  • Viridian reports strong launch of Lumvoa and outlines broader TED strategy

    Viridian describes the launch of Lumvoa as successful: within six weeks it reached 95% of the top 2,000 prescribing physicians, and payers indicate reimbursement levels comparable to TEPEZZA. The company is relying on existing payer infrastructure but expects delayed revenue due to authorization processes and billing rules until delivery to specialty distributors. Viridian plans a subcutaneous version (Elegrobart) with a BLA filing in Q1 2027 and is also developing programs such as a TSHR antagonist and an FcRn therapeutic program to expand the franchise. Management sees substantial untapped market potential, especially among chronic TED patients, and emphasizes market expansion rather than zero-sum competition. » Więcej na de.investing.com


  • Viridien reports strong order growth; stock jumps after Q2 data

    Viridien’s stock rose about 14.7% after Q2 figures following a marked increase in the order backlog in geosciences to USD 306m (up 33% since March). Major project awards from IOCs and NOCs in the Gulf of Mexico, Africa and the Middle East drove the volume; analysts view this as an early sign of broader revenue recovery. The EDA segment reached an adjusted EBITDA margin of 60% and the company confirmed its full-year target of USD 100m net cash flow for 2026. Viridien also filed the interim report with the AMF, providing additional transparency and investor confidence. » Więcej na de.investing.com


  • Viridian Therapeutics' Lumvoa seen as differentiated treatment for thyroid eye disease, analysts raise targets

    Goldman Sachs raised its target for Viridian Therapeutics to $39 and kept a Buy rating, citing Lumvoa's stronger proptosis improvement, promising safety profile and more convenient dosing versus Tepezza. Truist raised its target to $38, reiterated Buy and highlighted Lumvoa's focus on underserved markets, parity pricing and projected significant 2027 revenue with a franchise extension planned for Q1 2027. Viridian's broader pipeline includes Veligrotrug, Elegrobart, an anti‑TSHR program and FcRn inhibitors VRDN‑008 and VRDN‑006. » Więcej na finance.yahoo.com


  • Viridien expects markedly negative quarterly result and issues annual forecast

    Viridien will release results for the quarter ended June 30, 2026 on July 30, 2026; one analyst estimates EPS for the most recent quarter at -1.81 USD per share versus 0.67 EUR a year earlier. Two analysts see quarterly revenue at 237.0 million USD versus 206.7 million EUR in the year-ago quarter. Five analysts forecast an average EPS of 9.94 USD for the current fiscal year and four analysts expect revenue averaging 1.12 billion USD (prior year 948.5 million EUR). » Więcej na finanzen.net


  • Viridian Therapeutics gains commercial edge after Lumvoa approval as analysts raise price targets

    Following FDA approval of Lumvoa, Viridian Therapeutics priced the treatment at $450,000 per course and secured a label covering both active and chronic thyroid eye disease, which analysts say strengthens its commercial position. Wedbush raised its price target to $43 and maintained an Outperform rating, citing limited payer resistance, while Truist increased its target to $38 and reiterated a Buy rating, noting Lumvoa's convenient dosing and expected rapid adoption. Viridian plans a subcutaneous formulation with a BLA submission expected in Q1 2027 and anticipates meaningful revenue by 2027 from the underpenetrated TED market. » Więcej na finance.yahoo.com

Dane finansowe

W ostatnim kwartale Viridian Therapeutics Aktie osiągnęła przychody w wysokości 22,74 mln € i zysk netto w wysokości -89,35 mln €

(EUR) wrzesień 2026
YoY
Przychody 22,74 mln 62,19%
Zysk brutto 21,39 mln 64,43%
Zysk netto -89,35 mln 203,07%
EBITDA -89,28 mln 208,81%

Dane fundamentalne

Wskaźnik Wartość
Kapitalizacja rynkowa
3,1 mld €
Liczba akcji
113,56 mln
Maksimum/minimum z 52 tygodni
31,25 € - 12,01 €
Dywidendy Nie
Beta
0,96
C/Z (PE Ratio)
-7,74
PEG (PEG Ratio)
0,42
C/WK (PB Ratio)
5,85
C/S (PS Ratio)
129,32

Profil spółki

Viridian Therapeutics, Inc., spółka biotechnologiczna, opracowuje terapie dla pacjentów cierpiących na poważne choroby. Firma rozwija VRDN-001, humanizowane przeciwciało monoklonalne anty-IGF-1R, które znajduje się w badaniu klinicznym fazy 1/2 w leczeniu choroby oczu tarczycowej (TED); VRDN-002, przeciwciało IGF-1R, będące w badaniu klinicznym fazy 1; oraz VRDN-003, terapeutyczne przeciwciało kierowane przeciwko IGF-1R, przeznaczone do leczenia TED. Spółka wcześniej funkcjonowała pod nazwą Miragen Therapeutics, Inc. i w styczniu 2021 roku zmieniła nazwę na Viridian Therapeutics, Inc. Viridian Therapeutics, Inc. została założona w 2006 roku i ma siedzibę w Waltham w stanie Massachusetts.

Nazwa
Viridian Therapeutics Aktie
CEO
Stephen F. Mahoney
Siedziba Waltham, ma
Stany Zjednoczone
Strona internetowa
Sektor
Ochrona zdrowia
Branża
Ochrona zdrowia: sprzęt i produkty
Debiut giełdowy
18.06.2014
Pracownicy 252

Symbole giełdowe

Giełda Symbol
NASDAQ
VRDN
London Stock Exchange
0K1R.L
Frankfurt
1S1.F
Düsseldorf
1S1.DU
London
0K1R.L
🍪

Parqet  używa plików cookie. Dowiedz się więcej